The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico-Reference-Cited by-同舟云学术

The CNIC-polypill improves atherogenic dyslipidemia markers in patients at high risk or with cardiovascular disease: Results from a real-world setting in Mexico

Published:2020-08 Issue: Volume:29 Page:100545
ISSN:2352-9067
Container-title:IJC Heart & Vasculature
language:en
Short-container-title:IJC Heart & Vasculature

Author:

Gómez-Álvarez Enrique,Verdejo Juan,Ocampo Salvador,Ponte-Negretti Carlos I.,Ruíz Emilio,Ríos Marco Martínez

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference41 articles.

1. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

2. Total cardiovascular risk: a new treatment concept;Mancia;J. Hypertens. Suppl.,2006

3. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences;Chowdhury;Eur. Heart J.,2013

4. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

5. 2018 ESC/ESH Guidelines for the management of arterial hypertension

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efectividad de la polipíldora CNIC en prevención cardiovascular secundaria en el subgrupo de pacientes del estudio NEPTUNO con dosis de atorvastatina de 20 mg;Archivos de Cardiología de México;2024-06-07

2. The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease;BMC Gastroenterology;2024-05-10

3. The cardiovascular polypill as baseline treatment improves lipid profile and blood pressure regardless of body mass index in patients with cardiovascular disease. The Bacus study;PLOS ONE;2023-08-25

4. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial;BMC Cardiovascular Disorders;2022-12-22

5. Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study;Journal of Health Economics and Outcomes Research;2022-11-22